GT
BBIO icon

Glenmede Trust’s BridgeBio Pharma BBIO Stock Holding History

Glenmede Trust’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,656
Closed -$1.01M – 1499
2026
Q1 		$1.01M Sell
13,656
-7,511
-35% -$544K 0.01% 734
2025
Q4 		$1.62M Buy
+21,167
New +$1.39M 0.01% 604
2025
Q1 		$453K Sell
13,098
-21
-0.2% -$708 ﹤0.01% 944
2024
Q4 		$360K Sell
13,119
-3,196
-20% -$82.6K ﹤0.01% 1035
2024
Q3 		$415K Buy
16,315
+187
+1% +$4.91K ﹤0.01% 997
2024
Q2 		$409K Buy
16,128
+194
+1% +$5.3K ﹤0.01% 975
2024
Q1 		$493K Buy
15,934
+929
+6% +$31.6K ﹤0.01% 930
2023
Q4 		$606K Sell
15,005
-1,489
-9% -$44.7K ﹤0.01% 838
2023
Q3 		$435K Sell
16,494
-3,440
-17% -$97.6K ﹤0.01% 884
2023
Q2 		$331K Hold
19,934
– – ﹤0.01% 956
2023
Q1 		$331K Buy
+19,934
New +$232K ﹤0.01% 961
2020
Q2 		– Sell
-41
Closed -$1K – 2443
2020
Q1 		$1K Hold
41
– – ﹤0.01% 2915
2019
Q4 		$1K Buy
+41
New +$1.14K ﹤0.01% 2915

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Glenmede Trust's BBIO Position: Q2 2026 in Review

Glenmede Trust sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 13,656 shares — an estimated $1.01M sold.

Glenmede Trust first reported a position in BBIO in Q4 2019 and held it in 13 quarters. The position peaked at $1.62M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Glenmede Trust reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
  • Glenmede Trust sold 13,656 BridgeBio Pharma shares in Q2 2026, an estimated $1.01M.
  • Glenmede Trust first reported a position in BridgeBio Pharma in Q4 2019 and held it in 13 quarters.
  • Glenmede Trust's BridgeBio Pharma position peaked at $1.62M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.